Schering AG and Novartis Agree on Joint Commercialization of Novel Cancer Drug
Separate License Agreement for Ophthalmic Use Signed
27-Jan-2005 -
Schering AG, Germany announced that, following regulatory approvals, it will co-promote the novel oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK) for all oncology indications together with Novartis Pharma AG in Europe, North America and Japan. This agreement will enable both Schering and ...
angiogenesis
Germany
license agreements
+3